160 mg ABT + LPV/r | 320 mg ABT + LPV/r | |
---|---|---|
Randomized and treated | 10 | 10 |
Excluded | 1 | 1 |
SS for safety analysis | 10 | 10 |
ITT for efficacy analysis | 9 | 9 |
Sex (male/female) | 8/2 | 7/3 |
Race (Han/other) | 9/1 | 10/0 |
Age (years) | 31.9 (18~48) | 37.4 (24~47) |
Body weight (kg) | 67.8 (53~88) | 65.4 (53~76) |
BMI (kg/m2) | 22.8 (19~27) | 22.8 (18~26) |
Baseline HIV-1 RNA (log10 copies/ml) | 4.27 (3.53~4.70) | 4.27 (3.32~5.14) |
Baseline CD4 (cell/μl) | 517.0 (350~774) | 566.6 (350~1070) |